Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leela Barham

Set Alert for Articles By Leela Barham

Latest From Leela Barham

Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah

Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.

Pricing Strategies Europe

Payment For Outcomes Key To EU Market Access for Yescarta

Payment for outcomes has played an important role in enabling Gilead to secure reimbursement for Yescarta in some EU markets. It is likely to be the key focus for the company as it works to expand patient access to the potentially transformative CAR-T therapy across Europe.

Europe France

UK Industry Sets Out Key Asks On NICE’s Methods Review

As the National Institute for Health and Care Excellence conducts a review of its health technology assessment methods, the Association of the British Pharmaceutical Industry has laid out the key changes it would like to see.

Health Technology Assessment Pricing Debate

£197m Payments Made Under New UK Pricing Scheme But Access Promises Still To Materialize

Payments have now been made under the UK’s 2019 pricing and access to branded medicines scheme, but industry will have to wait longer for promises on access to materialize.

Pricing Strategies Market Access
See All